Nature Medicine | Spoonful of Medicine
ISSCR 2010: Will reprogrammed cells improve drug discovery?
The pharmaceutical industry has had a notoriously abysmal success rate at turning promising compounds into approved medicines. The usual number that gets tossed around is that only one in ten drug candidates will prove safe and effective. But the true success rate might be closer to one in 35, according to Corey Goodman, former president of Pfizer’s Biotherapeutics and Bioinnovation Center and now chairman of the board at iPierian, a South San Francisco-based biotech focused on using induced pluripotent stem (iPS) cells in drug discovery.
Recent comments
Real-time tissue analysis could guide brain tumor surgery
Bundled RNA balls silence brain cancer gene expression
Ebola outbreak in West Africa lends urgency to recently-funded research